|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
Valuation Estimation |
EPS (Current/Estimated)
-1.91/-1.85
|
Enterprise Value
101.49M
|
Balance Sheet |
Book Value Per Share
4.80
|
Cash Flow |
Cash Flow Yield
--
|
Income Statement |
Total Revenue
802.00K
|
Operating Revenue Per Share
0.34
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Quotes are at least 15-min delayed:2024/05/16 03:56 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
|
|||
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer. |